Login to Your Account



Washington Roundup

Panel Backs Questcor Spasms Drug, but Investors Still Jittery

By Donna Young


Monday, May 10, 2010
WASHINGTON - Perhaps it was the hangover from Thursday's "2:45 p.m. Wall Street crash," in which the Dow Jones Industrial Average spiraled nearly 1,000 points before minutes later somewhat bouncing back, that had Questcor Pharmaceuticals Inc.'s investors jittery Friday, despite an FDA panel's support for approval of the company's Acthar Gel (repository corticotrophin injection) as a therapy for infantile spasms. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription